VFC Resolution: Vaccines to Prevent COVID-19

Jeanne M. Santoli (jsantoli@cdc.gov)
Immunization Services Division
National Center for Immunization and
Respiratory Diseases
October 2022





Overview

Purpose of the Resolution

The purpose of this resolution is to add vaccines for the prevention of COVID-19 to the VFC program.

Eligible Groups

All children aged 6 months through 18 years

Recommended Schedule/Dosage Intervals

COVID-19 vaccines that are either authorized under Emergency Use Authorization (EUA) or approved under a Biologics License Application (BLA) are to be administered according to the most recent age- and vaccine-appropriate schedule included in CDC's Interim Clinical Considerations for COVID-19 vaccines (https://www.cdc.gov/vaccines/covid-19/clinicalconsiderations/covid-19-vaccines-us.html).

Recommended Dosage/Contraindications

Recommended dosage

Dosage information is available online at: COVID-19 Vaccines | FDA.

Contraindications and Precautions

 Contraindications and precautions are available in CDC's Interim Clinical Considerations for COVID-19 vaccines

(https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html).

Vaccine Availability through VFC

- COVID-19 vaccines will not be available through the VFC program immediately following the passage of this resolution because they remain available for all Americans under the USG's National COVID-19 Response.
- Following the passage of this resolution, CDC will begin the steps necessary to award contracts for COVID-19 vaccines.
- Once COVID-19 vaccines are commercialized and no longer available under the USG's National COVID-19 Response, VFC providers will be able to order the vaccines through the VFC program.
- The timeline for commercialization of COVID-19 vaccines in the US has not yet been finalized.